Dana-Farber
Computational Tool Tracks Genetic Variation Effects of Off-Target Gene Editing
Researchers came up with a strategy for predicting off-target edits related to genetic variation, using it to assess off-target variant effects on a potentially therapeutic guide RNA.
St. Jude, Broad Institute, Dana-Farber Partner to Advance Pediatric Cancer Research
The institutions have invested $60 million into the Pediatric Cancer Dependencies Accelerator to study cancer vulnerabilities and develop treatments.
Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients
After documenting excess TMB estimates in non-European cancer patients assessed by tumor-only sequencing, researchers came up with a calibration strategy to address the issue.
By tuning the basecaller with accurate telomere data, researchers were able to correct extensive repeat-calling errors in telomeres by nanopore sequencing.
Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change
Premium
Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it.